Agentix Corp (PK:AGTX)

Feb 15, 2022 07:00 am ET
CEO Presenting on the Emerging Growth Conference on February 16 Register Now
EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 25th Emerging Growth Conference. The Emerging...
Jan 04, 2022 08:52 am ET
AGENTIX Discusses 2022 Clinical Development Efforts and Potential Uplisting with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - January 4, 2022) - The Stock Day Podcast welcomed AGENTIX (OTC Pink: AGTX) ("the Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of metabolic diseases including type 2 diabetes mellitus, chronic obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). CEO of the Company, Rudy Mazzocchi, joined Stock Day host Everett Jolly.
Dec 21, 2021 05:00 am ET
AGENTIX and RTI International Announce Worldwide Exclusive License and Services Agreement
New York, New York--(Newsfile Corp. - December 21, 2021) - AGENTIX Corporation (OTC Pink: AGTX), a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of metabolic diseases, announced today it has entered into an amendment to a Patent and Know-How License Agreement between the parties, dated October 22, 2021, a worldwide exclusive license and services agreement with Research Triangle Institute, dba RTI International ("RTI"), a nonprofit research institute, concerning the commercialization of certain RTI therapeutic assets for the treatment of metabolic diseases. Evidence generated in pre-clinical models provides a compelling case for efficacy in the treatment of Non-alcoholic Fatty Liver Disease ("NAFLD") and Non-alcoholic Steatohepatitis ("NASH"), Type 2 Diabetes ("T2D"), and Obesity1. Under the amended agreement, AGENTIX is obligated to complete Phase I clinical trials by January 15, 2023.
Sep 08, 2021 08:00 am ET
AGENTIX Corporation and the National Health Research Institutions Announce Worldwide Exclusive License Agreements
New York, New York--(Newsfile Corp. - September 8, 2021) - AGENTIX Corp. (OTC Pink: AGTX), a pharmaceutical company focused on developing innovative therapeutic treatments targeting the endocannabinoid system (ECS) for the treatment of metabolic diseases, announced today it had entered into a worldwide exclusive license agreement and technology transfer agreement with the National Health Research Institutes ("NHRI") of Taiwan ROC, a nonprofit research institute, concerning the development and commercialization of DBPR211, an innovative new chemical entity with pre-clinical evidence demonstrating efficacy as a treatment for Obesity, Type 2 Diabetes (T2D), and Non-Alcoholic Fatty Liver Disease (NAFLD). This technology is a peripherally restricted cannabinoid receptor 1 antagonist that has successfully completed preliminary pre-clinical and in vivo testing requirements, including demonstrating it does not cross the blood brain barrier.
Nov 11, 2020 09:00 am ET
Agentix Biopharma CEO, Rudy Mazzocchi, Discusses the Company's Growth Strategy with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - November 11, 2020) - The Stock Day Podcast welcomed Agentix Biopharma (OTC Pink: AGTX) ("the Company"), a biotechnology company focused on the development of synthetic agonists, inverse agonists and antagonists which modulate the endocannabinoid system (ECS). CEO of the Company, Rudy Mazzocchi, joined Stock Day host Everett Jolly.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.